
FDA gives clearance for skin resurfacing device
A fractional nonablative laser module, the ResurFX for the Lumenis M22 platform, has been given 510(k) clearance from the Food and Drug Administration.
A fractional nonablative laser module, the ResurFX for the Lumenis M22 platform, has been given 510(k) clearance from the Food and Drug Administration.
The ResurFX module has a 1,565 nm fiber
“The ResurFX module with the CoolScan scanner allows me to treat patients faster and with greater efficacy, without having to compromise on patient comfort and safety,” Mitchel P. Goldman, M.D., volunteer clinical professor of dermatology, University of California, San Diego, said in the statement.
To get weekly news and analysis for today's skincare specialists,
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















